ArticleWorld journal of gastroenterology2018
Budd-Chiari syndrome in China: A 30-year retrospective study on survival from a single center.
Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Budd-Chiari Syndrome: Presentation, Management, and Prognosis.The American journal of gastroenterology · 2026Review
- Next-Generation Sequencing Identifies Novel Germline Mutations in Patients with Budd-Chiari Syndrome-Associated Hepatocellular Carcinoma.Digestive diseases and sciences · 2025Article
- Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature.World journal of clinical oncology · 2023Review
- AL amyloidosis with primary presentation of multiple serous cavity effusion and severe cholestasis: a case report and review of literature.BMC gastroenterology · 2022Review
- Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis.Frontiers in oncology · 2022Article
- An Update on the Management of Budd-Chiari Syndrome.Digestive diseases and sciences · 2021Review
- A case report of membranous occlusion of the subclavian vein: a rare cause of McCleery syndrome.Annals of translational medicine · 2021Article
- Restenosis after recanalization for Budd-Chiari syndrome: Management and long-term results of 60 patients.World journal of clinical cases · 2020Article
- Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report.World journal of clinical cases · 2019Article
- Splanchnic Vein Thrombosis: Current Perspectives.Vascular health and risk management · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate 30-year treatment outcomes associated with Budd-Chiari syndrome (BCS) at a tertiary hospital in China.
methodsA total of 256 patients diagnosed with primary BCS at our tertiary hospital between November 1983 and September 2013 were followed and retrospectively studied. Cumulative survival rates and cumulative mortality rates of major causes were calculated by Kaplan-Meier analysis, and the independent predictors of survival were identified using a Cox regression model.
resultsThirty-four patients were untreated; however, 222 patients were treated by medicine, surgery, or interventional radiology. Forty-four patients were lost to follow-up; however, 212 patients were followed, 67 of whom died. The symptom remission rates of treated and untreated patients were 81.1% (107/132) and 46.2% (6/13), respectively (
conclusionLong-term survival is satisfactory for treated Chinese patients with BCS. Hepatocellular carcinoma is a chronic complication and should be monitored with long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.